Since 2004, Molecular Health has stood for transforming big data into precise, actionable decisions for all stakeholders in healthcare. Their cloud-based Dataome® technology platform analyzes the molecular and clinical data of individual patients against the world’s medical, biological, and pharmacological knowledge, to drive more precise diagnostic, therapeutic, and drug safety decisions.
Their products are used across the healthcare sector, as more precise ways of practicing medicine impact the treatment of patients and the development of effective drugs, requiring ever more complex levels of data interpretation.
The company is financed by Dievini Hopp BioTech, an investment vehicle of former SAP CEO and founder Dietmar Hopp.
Molecular Health is a leading biomedical company that is transforming molecular data and medical knowledge into actionable information to support evidence-based clinical and therapeutic decisions. Molecular Health has built a technology platform that changes the way diseases are analyzed, understood and treated.
Molecular Health enables scalable precision medicine applications by combining the molecular and clinical data of individual patients with all of the world’s relevant biomedical knowledge. Molecular Health’s biomedical database draws from 24 million scientific and medical publications, 76,000 drug-to-drug interactions, 6,000 biomarker facts for drug efficacy and safety, 85,000 gene variants, 40,000 drugs, 109,000 clinical trials, 270,000 protein interactions and 7 million patient medical records for drug safety, among other data, and it is regularly updated.
Molecular Health currently offers a suite of products to fit the needs of the medical and therapeutic communities.
Molecular Health Inc., headquartered in Boston, Massachusetts is a wholly owned subsidiary of Molecular Health GmbH, headquartered in Heidelberg, Germany.
Where is Molecular Health